Apogee Therapeutics Inc
APGE
Company Profile
Business description
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Contact
221 Crescent Street
Building 17, Suite 102b
WalthamMA02453
USAT: +1 650 394-5230
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
196
Stocks News & Analysis
stocks
Will undervalued ASX share show progress in results?
Investors will get to see if the new strategy and capital management framework are working.
stocks
10 best US dividend aristocrats to buy now for 2026
These undervalued stocks with economic moats have increased their dividends for 25 consecutive years or more.
stocks
What to expect from the January Fed meeting
Central bankers are likely to hold interest rates steady, but Wall Street is focused on life after Powell.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,250.60 | 50.70 | -0.55% |
| CAC 40 | 8,059.79 | 93.03 | -1.14% |
| DAX 40 | 24,803.68 | 90.76 | -0.36% |
| Dow JONES (US) | 49,003.41 | 408.99 | -0.83% |
| FTSE 100 | 10,159.40 | 48.40 | -0.47% |
| HKSE | 27,826.91 | 699.96 | 2.58% |
| NASDAQ | 23,817.10 | 215.74 | 0.91% |
| Nikkei 225 | 53,358.71 | 25.17 | 0.05% |
| NZX 50 Index | 13,412.87 | 98.01 | -0.73% |
| S&P 500 | 6,978.60 | 28.37 | 0.41% |
| S&P/ASX 200 | 8,933.90 | 40.40 | -0.45% |
| SSE Composite Index | 4,151.24 | 11.33 | 0.27% |